A panel of 9 repeatedly measured circulating proteins predicted adverse clinical events in chronic heart failure patients with high discriminative ability (cvAUC 0.88), outperforming standard biomarkers.
Cohort (n=250)
Blinded outcome assessment
Yes
250 stable ambulatory patients with chronic heart failure with reduced ejection fraction, followed for a median of 2.2 years to evaluate biomarker trajectories.
9-biomarker panel (NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, TfR, CHIT1) vs Standard biomarkers (NT-proBNP, hs-TnT, eGFR)
Composite of cardiac death, heart transplantation, LVAD implantation, and hospitalization for acute or worsened HF — cvAUC 0.88 (0.86-0.90)
Effect estimate: cvAUC 0.88 (95% CI 0.86-0.90)
The aim of our observational study was to derive a small set out of 92 repeatedly measured biomarkers with optimal predictive capacity for adverse clinical events in heart failure, which could be used for dynamic, individual risk assessment in clinical practice. In 250 chronic HFrEF (CHF) patients, we collected trimonthly blood samples during a median of 2.2 years. We selected 537 samples for repeated measurement of 92 biomarkers with the Cardiovascular Panel III (Olink Proteomics AB). We applied Least Absolute Shrinkage and Selection Operator (LASSO) penalization to select the optimal set of predictors of the primary endpoint (PE). The association between repeatedly measured levels of selected biomarkers and the PE was evaluated by multivariable joint models (mvJM) with stratified fivefold cross validation of the area under the curve (cvAUC). The PE occurred in 66(27%) patients. The optimal set of biomarkers selected by LASSO included 9 proteins: NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, transferrin receptor protein-1, and chitotriosidase-1, that yielded a cvAUC of 0.88, outperforming the discriminative ability of models consisting of standard biomarkers (NT-proBNP, hs-TnT, eGFR clinically adjusted) - 0.82 and performing equally well as an extended literature-based set of acknowledged biomarkers (NT-proBNP, hs-TnT, hs-CRP, GDF-15, ST2, PAI-1, Galectin 3) - 0.88. Nine out of 92 serially measured circulating proteins provided a multivariable model for adverse clinical events in CHF patients with high discriminative ability. These proteins reflect wall stress, remodelling, endothelial dysfunction, iron deficiency, haemostasis/fibrinolysis and innate immunity activation. A panel containing these proteins could contribute to dynamic, personalized risk assessment.Clinical Trial Registration: 10/05/2013 https://clinicaltrials.gov/ct2/show/NCT01851538?term=nCT01851538&draw=2&rank=1 .
Building similarity graph...
Analyzing shared references across papers
Loading...
Dominika Klimczak‐Tomaniak
Medical University of Warsaw
Marie de Bakker
Erasmus MC
Elke Bouwens
Erasmus MC Cancer Institute
Scientific Reports
Erasmus University Rotterdam
Erasmus MC
Medical University of Warsaw
Building similarity graph...
Analyzing shared references across papers
Loading...
Klimczak‐Tomaniak et al. (Fri,) conducted a cohort in Chronic heart failure with reduced ejection fraction (HFrEF) (n=250). 9-biomarker panel (NT-proBNP, ST2, vWF, FABP4, IGFBP-1, PAI-1, PON-3, TfR, CHIT1) vs. Standard biomarkers (NT-proBNP, hs-TnT, eGFR) was evaluated on Composite of cardiac death, heart transplantation, LVAD implantation, and hospitalization for acute or worsened HF (cvAUC 0.88, 95% CI 0.86-0.90). A panel of 9 repeatedly measured circulating proteins predicted adverse clinical events in chronic heart failure patients with high discriminative ability (cvAUC 0.88), outperforming standard biomarkers.
synapsesocial.com/papers/6a20557e6504ae8788d1f312 — DOI: https://doi.org/10.1038/s41598-022-06698-3
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: